{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below for Phase II patients.","groups":[{"description":"Patients receive 650 mg Acetaminophen and 50 mg Benadryl orally 30 minutes prior to MV-NIS then receive MV-NIS IV over 1 hour on day 1.","id":"OG000","title":"Phase II (Acetaminophen + Benadryl + MV-NIS)"}],"paramType":"NUMBER","populationDescription":"Only phase II patients who completed the study are included in this analysis. Phase II Cohort A and Phase II Cohort B were combined for this analysis due to accrual terminating early in Cohort B and to obtain the overall toxicity rate among Phase II patients.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Overall Toxicity Rate, Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) (Phase II)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}